It uses electromagnetic waves to target tumors and is available to patients for whom first- and second-line treatments have ...

Coherus BioSciences, Inc. ("Coherus,” NASDAQ: CHRS) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

locally advanced or metastatic hepatocellular carcinoma: Hepatobiliary cancers include a spectrum of invasive carcinomas arising in the liver, gall bladder, and bile ducts. The most common type of ...

Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.

Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...

The trillions of microbial cells in our gastrointestinal tract have their own genomes and metabolic products, many of which ...

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either ...

Incyte is abandoning its ALK2 blocker zilurgisertib, which it was trialing for myelofibrosis-associated anemia, while iTeos ...

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 ...

T-DXd improves progression-free survival vs physician’s choice, regardless of time to progression or endocrine resistance, in ...

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver ...